Latest Paricalcitol Stories
-- Three multi-dose sizes designed to reduce drug waste, improve dosing efficiency -- LAKE FOREST, Ill., Nov. 5, 2014 /PRNewswire/ -- Hospira, Inc.
Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo.
Almost a year's treatment with a vitamin D compound did not alleviate key structural and functional cardiovascular abnormalities in patients with kidney disease and cardiac enlargement.
PRAGUE, June 28, 2011 /PRNewswire/ -- The 48th ERA-EDTA congress was the setting for a wide range of new clinical data.
PRAGUE, June 25, 2011 /PRNewswire/ -- The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatinleads to a significant reduction in major atherosclerotic events among CKD-patients.
MARKHAM, ON, Feb.
- Growing in low tufty patches.